山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (3): 4-8.doi: 10.6040/j.issn.1673-3770.0.2017.138

• 变应性鼻结膜炎防治进展·专题笔谈 • 上一篇    下一篇

重视变应性鼻炎药物治疗的规范化和个体化

许昱,陶泽璋   

  1. 武汉大学人民医院耳鼻咽喉头颈外科, 湖北 武汉 430060
  • 收稿日期:2017-03-31 出版日期:2017-06-16 发布日期:2017-06-16
  • 通讯作者: 陶泽璋. E-mail:taozezhang@163.com

Pharmacotherapeutic strategies for allergic rhinitis:Ithe importance of individualization and normalization.

XU Yu,  TAO Zezhang   

  1. Department of Otolaryngology Head and Neck Surgery, RenminHospital of Wuhan University, Wuhan 430060, Hubei, China
  • Received:2017-03-31 Online:2017-06-16 Published:2017-06-16

摘要: 变应性鼻炎的发病率逐年增高,给患者生活质量带来严重影响。药物治疗是变应性鼻炎控制症状主要手段,相关药物各有特点。在进行药物治疗时应遵循规范性和个体化的原则,根据患者主要症状及症状严重程度合理用药,并根据疗效和不良反应情况适时进行药物的升级和降级。

关键词: 变应性鼻炎, 药物治疗, 个体化

Abstract: The prevalence of allergic rhinitis has increased in recently years. Pharmacotherapy is the main method to control the symptoms for the treatment of allergic rhinitis. A wide array of medical treatment options is available. Each drug has a different effect and speciality. Algorithms for management of allergic rhinitis AR and selection of drug should be based on each patients specific symptoms, and the presence of any comorbidities. Patient should be monitored to assess symptom control, therapy adjustment(step up/step down)is also needed.

Key words: Individualization, Allergic rhinitis, Pharmacotherapy

中图分类号: 

  • R765.21
[1] Wang XD, Zheng M, Lou HF, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011[J]. Allergy, 2016, 71(8):1170-1180.
[2] Juniper EF, Guyatt GH, O'Byrne PM, et al. Aqueous beclomethasonediproprionate nasal spray: regular versus “as required” use in the treatment of seasonal allergic rhinitis[J]. J Allergy Clin Immunol, 1990, 86(3):380-386.
[3] Juniper EF, Guyatt GH, Archer B, et al. Aqueous beclomethasonedipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of “as needed” use[J]. J Allergy Clin Immunol, 1993, 92(1 Pt 1):66-67.
[4] Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed(prn)[J]. Ann Allergy Asthma Immunol, 2003, 91(1):44-48.
[5] Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials[J]. BMJ, 1998, 317(7173):1624-1629.
[6] Yá(~overn)ez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis[J]. Ann Allergy Asthma Immunol, 2002, 89(5):479-484.
[7] Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class[J]. Ann Allergy Asthma Immunol, 2010, 104(1):13-29.
[8] Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis[J]. Am J Med, 2004, 116(5):338-344.
[9] Bielory L, Chun Y, Bielory BP, et al. Impact of mometasonefuroate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis[J]. Allergy, 2011, 66(5):686-693.
[10] Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthmaoutcomes in allergic rhinitis: a meta-analysis[J]. Allergy, 2013, 68(5):569-579.
[11] Ratner PH, Meltzer EO, Teper A. Mometasonefuroate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2009, 73(5):651-657.
[12] Allen DB, Meltzer EO, Jr LR, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year[J]. Allergy Asthma Proc, 2002, 23(6):407-413.
[13] Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasonefuroate aqueous nasal spray[J]. Pediatrics, 2000, 105(2):E22.
[14] Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray(mometasonefuroate)on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids[J]. Auris Nasus Larynx, 2013, 40(3):277-281.
[15] Simons FE. Advances in H1-antihistamines[J]. New Eng J Med, 2004, 351(21):2203-2217.
[16] Dizdar EA, Sekerel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2007, 71(6):843-849.
[17] Laekeman G, Simoens S, Buffels J, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice[J]. Respir Med, 2010, 4(5):615-625.
[18] Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(Suppl 1):S1-S43.
[19] Horak F, Zieglmayer UP, Zieglmayer R, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy[J]. Curr Med Res Opin, 2006, 22(1):151-157.
[20] Kaliner MA, Berger WE, Ratner PH, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis[J]. Allergy Asthma Immunol, 2011, 106(Suppl 2):S6-S11.
[21] Laforce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine[J]. Ann Allergy Asthma Immunol, 2004, 93(2):154-159.
[22] Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2009, 103(5):373-380.
[23] Carr WW, Ratner P, Munzel U, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis[J]. Allergy Asthma Proc, 2012, 33(6):450-458.
[24] Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review[J]. Drugs, 2007, 67(6):887-901.
[25] Van AJ, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period[J]. Allergy, 2003, 58(58):1268-1276.
[26] Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions[J]. Pediatr Pulmonol, 2009, 44(6):568-579.
[27] Mösges R, Klimek L. Todays allergic rhinitis patients are different: new factors that may play a role[J]. Allergy, 2007, 62(9):969-975.
[28] Anolik R. Clinical benefits of combination treatment with mometasonefuroate nasal spray and loratadinevsmonotherapy with mometasonefuroate in the treatment of seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(3):264-271.
[29] Can D, Tanaç R, Demir E, et al. Is the usage of intranasal glucocorticosteroids alone in allergic rhinitis sufficient?[J]. Allergy Asthma Proc, 2006, 27(3):248-253.
[30] Nasser M, Fedorowicz Z, Aljufairi H, et al. Antihistamines used in addition to topical nasal steroids for intermittent and persistent allergic rhinitis in children[J]. Cochrane Database Syst Rev, 2010, 7(7):CD006989.
[31] Hilberg O. Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge[J]. Allergy, 1995, 50(8):683-688.
[32] Ratner PH, Hampel F, Bavel JV, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(1):74-81.
[33] Hampel FC, Ratner PH, Van BJ, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device[J]. Ann Allergy Asthma Immunol, 2010, 105(2):168-173.
[34] Laforce CF, Carr W, Tilles SA, et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis[J]. Allergy Asthma Proc, 2010, 31(2):132-140.
[35] Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis[J]. J Allergy Clin Immunol, 2012, 129(129):1282-1289.e10.
[36] Rael EL, Ramey J, Lockey RF. Oxymetazoline hydrochloride combined with mometasone nasal spray for persistent nasal congestion(pilot study)[J]. World Allergy Organ J, 2011, 4(3):65-67.
[37] Meltzer EO, Bernstein DI, Prenner BM, et al. Mometasonefuroate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis[J]. Am J Rhinol Allergy, 2013, 27(2):102-108.
[38] Cingi C, Gunhan K, Gage-White L, et al. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis[J]. Laryngoscope, 2010, 120(9):1718-1723.
[39] Rodrigo GJ, Ya(~overn)ez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials[J]. Ann Allergy Asthma Immunol, 2006, 96(6):779-786.
[40] Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis.[J]. J Asthma, 2009, 46(9):878-883.
[41] Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall[J]. Ann Allergy Asthma Immunol, 2002, 88(6):592-600.
[42] Esteitie R, Detineo M, Naclerio RM, et al. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2010, 105(2):155-161.
[43] Goh BS, Ismail MI, Husain S. Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a randomised, double-blind, placebo-controlled study[J]. J Laryngol Otol, 2014, 128(3):242-248.
[44] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志, 2016, 51(1):6-24. Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis[J]. Chin J Otorhinolaryngol Head Neck Surg, 2016, 51(1):6-24.
[45] Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions.[J]. Allergy Asthma Proceed, 2013, 34(4):301-311.
[46] Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA(2)LEN and AllerGen)[J]. Allergy, 2008, 63(Suppl 86):8-160.
[1] 王坛,武珂,李连庆,宫丽丽. 皮下免疫治疗注射后出现全身不良反应的伴发因素及处理[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 71-74.
[2] 卢汉桂,林歆胜,姚丹勉,魏永新,李创伟. 变应性鼻炎大鼠IL-35的表达及对辅助性T细胞免疫调节的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 66-70.
[3] 浦洪波,杜晓东. 无锡地区2 000例变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 105-107.
[4] 代亚错,李靖,万保罗,臧艳姿,黄颖铭. 个体化治疗咽喉部海绵状血管瘤二例[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 110-112.
[5] 陈鸣,俞雪飞. 浅谈伴有变应性鼻炎的慢性鼻窦炎的治疗[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 18-22.
[6] 吴湘萍. 患者管理方式对变应性鼻炎舌下含服粉尘螨滴剂疗效的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 68-72.
[7] 李松,王宗贵,杨景朴,张竹萍. 鼻内镜下翼管神经切断术进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(1): 72-76.
[8] 郅莉莉,宋道亮. 嗜酸性粒细胞及IL5在上颌窦后鼻孔息肉与鼻息肉中表达的差异[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 43-46.
[9] 万文锦,王文,程雷. 尘螨变应性鼻炎皮下免疫治疗与舌下免疫治疗的荟萃分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 103-108.
[10] 朱新华. 变应性鼻炎冲击免疫治疗的临床应用[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 13-17.
[11] 史丽,赵莉,张红萍. 变应性鼻炎的长期抗炎治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 9-12.
[12] 刘静. 基于整体观念变应性鼻炎的中医辨证论治[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 28-30.
[13] 程雷,钱俊俊,田慧琴. 变应性鼻炎研究的若干进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 1-3.
[14] 刘英,叶小静,赵春丽,季青,黄谦. 季节性变应性鼻炎预防性治疗观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 37-40.
[15] 李莉珠,吴卿,易欣,田理. 变应性鼻炎中医证候动物模型的研究进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 60-63.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 赵利敏,倪坤,吴佳丽,陈淑梅,李晓艳. 婴幼儿吸气性喉喘鸣病因分析与治疗[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 49 -51 .
[2] 史春生1,张庆泉2,王强2,孙岩2,葛长艺1. 软腭缺损修复组织瓣的特点[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 86 -88 .
[3] 张令1,孙传义1,许安廷2. 以耳聋就诊的岩尖胆脂瘤1例[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 93 -94 .
[4] 吴彦桥,邸斌,李军,高晓红 . 鼻内镜下难治性鼻出血出血点寻找及止血策略[J]. 山东大学耳鼻喉眼学报, 2013, 27(4): 1 -3 .
[5] 罗惠秀,范春涛,邓延华. 阻塞性睡眠呼吸暂停低通气综合征患儿扁桃体腺样体切除术临床疗效分析[J]. 山东大学耳鼻喉眼学报, 2013, 27(4): 17 -20 .
[6] 郝颖娟1,杨庆松2,周跃华2,易省平1,翟长斌2. 飞秒激光在薄瓣LASIK手术中制作的角膜瓣厚度形态观察[J]. 山东大学耳鼻喉眼学报, 2013, 27(4): 26 -31 .
[7] 闻华明1,李海祥2. 应用三角函数法估算LASIK术后人工晶状体度数[J]. 山东大学耳鼻喉眼学报, 2013, 27(5): 74 -76 .
[8] 朱见,贺青卿,郑鲁明,范子义,赵国伟,侯蕾,史后彬 . cN0甲状腺微小乳头状癌淋巴结转移高危因素及行预防性清扫临床分析[J]. 山东大学耳鼻喉眼学报, 2013, 27(6): 9 -12 .
[9] 李少华,孙一帆,卢标清. 双软组织血管瓣填塞乳突术腔的临床研究[J]. 山东大学耳鼻喉眼学报, 2014, 28(1): 6 -7 .
[10] 魏希建1,阴瑞兰2,郭星3. 增殖诱导配体在喉鳞状细胞癌中的表达[J]. 山东大学耳鼻喉眼学报, 2014, 28(1): 14 -16 .